Since Clec9A<sup>+</sup> DCs constitutively present relevant neoepitopes in tumors but are suppressed in tumor microenvironments, we developed Clec9A-targeted STING or RIG-I liposomes to enhance endogenous tumor immunity.<h4>Methods</h4>Liposomes encapsulating RIG-I or the STING agonist MSA-1 and functionalised with Clec9A binding peptide WH were optimised for uptake by Clec9A<sup>+</sup> conventional and plasmacytoid DCs <i>in vivo</i>. Here, CLEC9A is linked to neoplasm.